| pubmed-article:12393660 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12393660 | lifeskim:mentions | umls-concept:C0024299 | lld:lifeskim |
| pubmed-article:12393660 | lifeskim:mentions | umls-concept:C0123759 | lld:lifeskim |
| pubmed-article:12393660 | lifeskim:mentions | umls-concept:C0431085 | lld:lifeskim |
| pubmed-article:12393660 | lifeskim:mentions | umls-concept:C1327616 | lld:lifeskim |
| pubmed-article:12393660 | lifeskim:mentions | umls-concept:C0024518 | lld:lifeskim |
| pubmed-article:12393660 | lifeskim:mentions | umls-concept:C1420799 | lld:lifeskim |
| pubmed-article:12393660 | lifeskim:mentions | umls-concept:C0439859 | lld:lifeskim |
| pubmed-article:12393660 | lifeskim:mentions | umls-concept:C0456387 | lld:lifeskim |
| pubmed-article:12393660 | lifeskim:mentions | umls-concept:C1880198 | lld:lifeskim |
| pubmed-article:12393660 | lifeskim:mentions | umls-concept:C0205221 | lld:lifeskim |
| pubmed-article:12393660 | lifeskim:mentions | umls-concept:C1515895 | lld:lifeskim |
| pubmed-article:12393660 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:12393660 | pubmed:dateCreated | 2003-1-1 | lld:pubmed |
| pubmed-article:12393660 | pubmed:abstractText | Cytokine gene-modified tumor cells have increased immunogenicity and retain the antigenic repertoire of a particular neoplasia. However, practical concerns have led to an increased interest in allogeneic gene-transduced bystander cells as a broader source of cytokines for autologous tumor cell-based vaccines. Here, we show that allogeneic B78H1 major histocompatibility complex (MHC) class I-negative and -positive (H-2K(b)- and D(b)-transfected) cells induced cytotoxic T lymphocytes (CTLs) and protection in BALB/c mice at comparable levels in response to a challenge with C26 (H-2(d)) colon carcinoma cells sharing the tumor-associated antigen envelope glycoprotein 70 (env-gp70) with both cell lines. Class I-negative B78H1 cells transduced to express interleukin-12 (IL-12) and mixed with autologous A20 tumor cells led to eradication of preestablished A20 lymphoma in 50% or 100% of treated mice after 3 or 4 vaccinations, respectively, whereas A20 cells alone or mixed with nontransduced B78H1 cured none or 50% of mice after 3 or 4 vaccinations, respectively. Immunization with the IL-12-producing bystander cell line increased tumor-specific proliferation and type 1 cytokine production by CD4(+) T cells. By contrast, CD4 T-cell function appeared impaired after immunization with A20 cells alone or mixed with B78H1 cells. Indeed, only CD4(+) T cells from IL-12-treated mice could be restimulated with anti-OX40 monoclonal antibody (mAb) in place of a fourth cellular boost. Moreover, the IL-12-based tumor vaccine induced expansion of tumor-specific interferon-gamma (IFN-gamma)-producing CD8(+) T cells. These results are clinically relevant for the development of feasible IL-12 cancer vaccines based on engineered class I-negative bystander cells. | lld:pubmed |
| pubmed-article:12393660 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12393660 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12393660 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:12393660 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12393660 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12393660 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12393660 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12393660 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12393660 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12393660 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12393660 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12393660 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12393660 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:12393660 | pubmed:issn | 0006-4971 | lld:pubmed |
| pubmed-article:12393660 | pubmed:author | pubmed-author:ColomboMario... | lld:pubmed |
| pubmed-article:12393660 | pubmed:author | pubmed-author:CurtiAntonioA | lld:pubmed |
| pubmed-article:12393660 | pubmed:author | pubmed-author:ParenzaMariel... | lld:pubmed |
| pubmed-article:12393660 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12393660 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:12393660 | pubmed:volume | 101 | lld:pubmed |
| pubmed-article:12393660 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12393660 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12393660 | pubmed:pagination | 568-75 | lld:pubmed |
| pubmed-article:12393660 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:12393660 | pubmed:meshHeading | pubmed-meshheading:12393660... | lld:pubmed |
| pubmed-article:12393660 | pubmed:meshHeading | pubmed-meshheading:12393660... | lld:pubmed |
| pubmed-article:12393660 | pubmed:meshHeading | pubmed-meshheading:12393660... | lld:pubmed |
| pubmed-article:12393660 | pubmed:meshHeading | pubmed-meshheading:12393660... | lld:pubmed |
| pubmed-article:12393660 | pubmed:meshHeading | pubmed-meshheading:12393660... | lld:pubmed |
| pubmed-article:12393660 | pubmed:meshHeading | pubmed-meshheading:12393660... | lld:pubmed |
| pubmed-article:12393660 | pubmed:meshHeading | pubmed-meshheading:12393660... | lld:pubmed |
| pubmed-article:12393660 | pubmed:meshHeading | pubmed-meshheading:12393660... | lld:pubmed |
| pubmed-article:12393660 | pubmed:meshHeading | pubmed-meshheading:12393660... | lld:pubmed |
| pubmed-article:12393660 | pubmed:meshHeading | pubmed-meshheading:12393660... | lld:pubmed |
| pubmed-article:12393660 | pubmed:meshHeading | pubmed-meshheading:12393660... | lld:pubmed |
| pubmed-article:12393660 | pubmed:meshHeading | pubmed-meshheading:12393660... | lld:pubmed |
| pubmed-article:12393660 | pubmed:meshHeading | pubmed-meshheading:12393660... | lld:pubmed |
| pubmed-article:12393660 | pubmed:meshHeading | pubmed-meshheading:12393660... | lld:pubmed |
| pubmed-article:12393660 | pubmed:meshHeading | pubmed-meshheading:12393660... | lld:pubmed |
| pubmed-article:12393660 | pubmed:meshHeading | pubmed-meshheading:12393660... | lld:pubmed |
| pubmed-article:12393660 | pubmed:meshHeading | pubmed-meshheading:12393660... | lld:pubmed |
| pubmed-article:12393660 | pubmed:meshHeading | pubmed-meshheading:12393660... | lld:pubmed |
| pubmed-article:12393660 | pubmed:meshHeading | pubmed-meshheading:12393660... | lld:pubmed |
| pubmed-article:12393660 | pubmed:year | 2003 | lld:pubmed |
| pubmed-article:12393660 | pubmed:articleTitle | Autologous and MHC class I-negative allogeneic tumor cells secreting IL-12 together cure disseminated A20 lymphoma. | lld:pubmed |
| pubmed-article:12393660 | pubmed:affiliation | Immunotherapy and Gene Therapy Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy. | lld:pubmed |
| pubmed-article:12393660 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:12393660 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12393660 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12393660 | lld:pubmed |
